ReviewKidney & blood pressure research2026
Expert Opinion on the Conceptual, Clinical, and Therapeutic Aspects of Fabry Nephropathy: A Nephrologists' Perspective.
Review in Kidney & blood pressure research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProgressive nephropathy (Fabry nephropathy), as observed in both the early-onset and later-onset types of Fabry disease and in as many as 50% of males and 20% of females, represents a major driver of overall disease burden in this population. Nonetheless, recognizing and diagnosing Fabry nephropathy remains clinically demanding for nephrologists given its pivotal role in altering disease progression and improving patients' quality of life. Therapeutics presents additional complexity as evidence-based criteria for treatment and prognostic algorithms remain limited. SUMMARY: Against this background, this expert opinion aims to address the current knowledge on conceptual, clinical, and therapeutic aspects of Fabry nephropathy from a nephrologist's perspective and to provide a guidance document for the best practice in the management and monitoring of the disease. KEY MESSAGES: The participating experts considered the indispensable role of heightened disease awareness among nephrologists, the maintenance of a high diagnostic index in symptomatic individuals, and the importance of systematic screening of at-risk populations to enable prompt identification of Fabry nephropathy. This is particularly important in the current availability of enzymatic and genetic screening tests and the specific disease-modifying treatments capable of decelerating kidney function deterioration when initiated at an early disease stage. Implementation of a multidisciplinary approach with an experienced team of clinicians, and continued monitoring and assessment of clinical status are considered critical to optimal patient care, as well as the timely initiation of ERT in conjunction with appropriately selected adjunctive treatments within a care plan individualized to the patient's clinical signs and symptoms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.